Global Stroke Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
33.00 Billion
USD
58.93 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 33.00 Billion |
 시장 규모(예측 연도) |
USD 58.93 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
글로벌 뇌졸중 시장 세분화, 유형(허혈성 뇌졸중, 일과성 허혈 발작 (TIA), 출혈성 뇌졸중 ), 진단 및 치료(진단 및 치료), 성별(여성 및 남성), 최종 사용자(병원 및 진료소, 전문 진료소, 외래 수술 센터, 재택 치료, 실험실 및 기타), 유통 채널(직접, 소매 및 온라인) - 2032년까지의 산업 동향 및 예측
뇌졸중 시장 분석
글로벌 뇌졸중 시장은 의료 산업 내에서 빠르게 성장하는 분야로, 뇌졸중 환자의 예방, 진단, 치료 및 재활을 위한 제품과 서비스에 중점을 두고 있습니다. 이 시장의 주요 구성 요소는 의약품(혈전용해제, 항혈소판제, 항응고제 등), 의료기기(혈관 스텐트, 신경 보호 장치 등), 재활 장비(물리 치료 도구 및 언어 치료 보조기 등)입니다. 뇌졸중 예방에 대한 인식 제고, 의료 기술의 발전, 그리고 뇌졸중에 더 취약한 고령 인구 증가 등의 요인이 이러한 성장을 견인하고 있습니다. 고혈압과 당뇨병을 비롯한 비전염성 질환의 유병률 증가는 효과적인 뇌졸중 치료에 대한 수요를 더욱 증가시키고 있습니다.
뇌졸중 시장 규모
글로벌 뇌졸중 시장은 2024년 330억 달러에서 2032년 589억 3천만 달러로 성장할 것으로 예상되며, 2025년부터 2032년까지의 예측 기간 동안 연평균 성장률(CAGR) 7.8%로 성장할 것으로 전망됩니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 기업 등 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크 등이 포함되어 있습니다.
뇌졸중 시장 동향
“뇌졸중 진단 및 관리를 위한 첨단 신경영상 기술과 원격진료 솔루션 도입 증가”
전 세계 뇌졸중 시장의 주목할 만한 추세 중 하나는 뇌졸중 진단 및 관리를 위한 첨단 신경영상 기술과 원격진료 솔루션 도입 증가입니다. 뇌졸중 치료에서 신속한 개입의 중요성에 대한 인식이 높아짐에 따라, MRI 및 CT 스캔과 같은 정교한 영상 기술을 활용하여 뇌졸중 유형을 더욱 빠르고 정확하게 진단하는 방향으로 크게 전환되고 있습니다. 또한, 원격진료는 특히 농촌 지역이나 의료 서비스가 부족한 지역에서 시의적절한 상담 및 원격 모니터링을 제공하는 데 필수적인 요소로 자리 잡고 있으며, 이를 통해 의료 전문가는 환자를 신속하게 평가하고 치료를 시작할 수 있습니다. 이러한 추세는 환자 치료 결과를 향상시킬 뿐만 아니라 뇌졸중 치료 과정 전반에 걸쳐 혁신과 투자를 촉진합니다.
보고서 범위 및 뇌졸중 시장 세분화
|
속성 |
스트로크 키 마켓 인사이트 |
|
다루는 세그먼트 |
|
|
포함 국가 |
미국, 캐나다, 멕시코, 독일, 프랑스, 영국, 네덜란드, 스위스, 러시아, 이탈리아, 스페인, 터키, 오스트리아, 폴란드, 노르웨이, 아일랜드, 기타 유럽 국가, 중국, 일본, 인도, 한국, 싱가포르, 말레이시아, 호주, 태국, 인도네시아, 필리핀, 베트남, 대만, 기타 아시아 태평양 국가, 사우디아라비아, UAE, 남아프리카 공화국, 이집트, 이스라엘, 쿠웨이트, 기타 중동 및 아프리카 국가, 브라질, 아르헨티나, 칠레, 페루, 기타 남미 국가 |
|
주요 시장 참여자 |
Bristol-Myers Squibb Company(미국), Boehringer Ingelheim International GmbH(독일), F. Hoffmann-La Roche Ltd(스위스), DAIICHI SANKYO COMPANY, LIMITED(일본), Sanofi(프랑스), Johnson & Johnson Services, Inc.(미국), Bayer AG(독일), Sandoz AG(스위스), Pfizer Inc.(미국), Medtronic(아일랜드), Abbott(미국), Viatris Inc.(미국), AstraZeneca(영국), Penumbra, Inc.(미국), GLENMARK PHARMACEUTICALS LTD(인도), Fresenius SE & Co. KGaA(독일), Teva Pharmaceuticals USA, Inc.(이스라엘), Lupin(인도), Amneal Pharmaceuticals LLC(미국) 등이 있습니다. |
|
시장 기회 |
|
|
부가가치 데이터 정보 세트 |
Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 적용 범위, 주요 기업 등 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함됩니다. |
뇌졸중 시장 정의
글로벌 뇌졸중 시장은 전 세계 뇌졸중 환자의 예방, 진단, 치료 및 재활에 관련된 다양한 제품, 서비스 및 기술을 아우릅니다. 여기에는 뇌졸중 치료의 복잡성을 해결하기 위한 다양한 의료기기, 의약품, 영상 장비 및 치료 솔루션이 포함됩니다. 이 시장은 인구 고령화, 생활 습관 변화, 그리고 뇌졸중 증상 및 치료 옵션에 대한 인식 제고로 인한 뇌졸중 발생률 증가에 의해 주도되고 있습니다. 또한, 의료 기술과 원격 진료의 발전은 다양한 인구 통계 및 의료 환경에서 환자 관리를 개선하고 뇌졸중 치료 결과를 개선하는 데 기여하며 시장 환경을 조성하고 있습니다.
뇌졸중 시장 동향
운전자
- 뇌졸중 발병률 증가로 인한 치료 수요 증가
뇌졸중 발생률 증가는 전 세계 뇌졸중 시장의 주요 동인으로, 치료 수요와 의료 인프라 모두에 영향을 미칩니다. 전 세계적으로 장애와 사망의 주요 원인인 뇌졸중은 고령화, 비활동적인 생활 방식, 고혈압, 당뇨병, 흡연, 그리고 열악한 식습관 등 다양한 위험 요인으로 인해 점점 더 흔해지고 있습니다. 기대수명이 증가하고 인구가 고령화됨에 따라 고혈압이나 심방세동과 같은 뇌졸중 유발 질환의 유병률 또한 증가하여, 뇌졸중으로 고통받는 사람들이 늘어나 즉각적인 치료와 장기적인 재활이 필요하게 되었습니다.
예를 들어,
2023년 5월, eClinicalMedicine에 게재된 논문에 따르면 뇌졸중은 전 세계적으로 두 번째 주요 사망 원인이자 세 번째 주요 장애 원인입니다. 지난 30년 동안 뇌졸중 발생률(70%)과 유병률(85%)이 증가했으며, 뇌졸중으로 인한 사망률(43%)도 증가했습니다.
- 고혈압 및 관상동맥 심장 질환 환자 증가
고혈압은 일반적으로 고혈압이라고 알려져 있으며, 동맥벽에 가해지는 혈액의 압력이 증가하는 질환입니다. 일반적으로 혈압이 130/80mmHg 이상으로 정의되며, 근본 원인에 따라 본태성(원발성) 또는 이차성으로 분류할 수 있습니다. 장기간 고혈압이 지속되면 여러 가지 심각한 건강 문제가 발생할 수 있으며, 그중 가장 심각한 문제 중 하나는 관상동맥 심장 질환입니다. 관상동맥 질환이라고도 하는 관상동맥 심장 질환은 심장 근육에 산소와 영양분을 공급하는 관상동맥에 지방이 점진적으로 축적(죽상경화증)되어 발생합니다. 이러한 동맥이 좁아지거나 막히면 심장으로 가는 혈류가 감소하여 흉통(협심증)이 발생하고, 심한 경우 심장마비가 발생합니다.
예를 들어,
2023년 9월, 팬 아메리칸 헬스 오가니제이션 저널(Pan American Health Organization Journal)에 발표된 논문에 따르면, 무증상인 경우가 많은 고혈압은 주요 사망 원인인 심혈관 질환의 발병에 상당한 영향을 미치는 것으로 나타났습니다. 노화, 비만, 그리고 잘못된 생활 습관과 같은 요인들이 유병률 증가를 촉진하고 있으며, 효과적인 치료법을 요구하고 있습니다.
기회
- 뇌졸중에 대한 첨단 치료법 개발
첨단 치료법 개발은 뇌졸중 치료 분야의 상당한 미충족 수요를 해결함으로써 전 세계 뇌졸중 시장에 중요한 기회를 제공합니다. 혈전 용해술이나 혈전 제거술을 통한 혈류 회복에 주로 초점을 맞춘 현재 치료법은 제한된 시간 내에만 효과가 있으며, 근본적인 신경 손상을 해결하지 못합니다. 신경 보호제, 세포 기반 치료법, 표적 약물 전달 시스템과 같은 첨단 치료법은 이러한 손상을 완화하고, 신경 회복을 촉진하며, 뇌졸중 환자의 장기적인 기능적 결과를 향상시킬 것으로 기대됩니다. 이는 장애 감소, 장기 요양 관련 의료비 절감, 그리고 생존자의 삶의 질 향상으로 이어져, 투자를 유치하고 더 효과적인 치료법에 대한 수요를 촉진함으로써 시장 잠재력을 확대할 것입니다.
예를 들어,
2022년 4월, 미국심장협회지(American Heart Association Journals)에 발표된 논문에 따르면 급성 허혈성 뇌졸중 치료는 지속적으로 발전하고 있습니다. 테넥테플라제(Tenecteplase)는 대체 혈전 용해제로 평가되었으며, 알테플라제만큼 효과가 적고 큰 혈관 혈전을 더 효과적으로 용해할 수 있다는 증거가 있습니다. 기계적 혈전 제거술을 이용한 혈관내 치료는 근위부 큰 혈관 폐색이 있는 신중하게 선택된 환자에서 뇌졸중 발병 후 최대 24시간까지 효과가 있는 것으로 나타났습니다.
- 뇌졸중 재활 서비스 확대
뇌졸중 재활 서비스 확대는 더욱 효과적인 회복 및 재활 프로그램에 대한 증가하는 수요를 충족함으로써 전 세계 뇌졸중 시장에 상당한 기회를 제공합니다. 현재 뇌졸중 생존자들은 상실된 운동 및 인지 기능을 회복하는 데 상당한 어려움을 겪고 있으며, 이는 장기 입원, 의료비 증가, 그리고 삶의 질 저하로 이어집니다. 전 세계 인구 고령화와 뇌졸중 발병률 증가에 따라, 뇌졸중 생존자의 개별적인 요구에 부응하는 향상된 재활 서비스에 대한 절실한 필요성이 대두되고 있습니다. 뇌졸중 재활 서비스 확대를 통해 의료 서비스 제공자와 의료비 지불자는 포괄적이고 개인화된 치료에 대한 충족되지 않은 수요를 충족하여 환자 치료 결과 개선, 의료비 절감, 그리고 환자 만족도 향상으로 이어질 수 있습니다.
예를 들어,
MDPI가 발표한 2023년 4월 논문에 따르면, 선진국들은 뇌졸중 환자를 위한 재활 서비스를 제공하기 위해 노력하고 있습니다. 신체 재활은 뇌졸중 환자의 알려진 합병증을 줄이거나 예방하는 동시에 삶의 질을 향상시킬 수 있습니다. 치료사는 기능 장애, 활동 제한, 그리고 회복 목표에 따라 적절한 중재 방법을 선택합니다.
제약/도전
- 높은 진단 비용
심장병과 뇌졸중은 수년간 전 세계적으로 사망률을 증가시킨 주요 요인 중 하나입니다. 뇌졸중은 가장 비용이 많이 드는 만성 질환 중 하나로 꼽힙니다. 매년 86만 8천 명 이상의 미국인이 심장병이나 뇌졸중으로 사망하며, 이는 전체 사망자의 3분의 1에 해당합니다. 뇌졸중 발생률이 증가함에 따라 진단 및 치료 비용도 수년간 증가했으며, 이는 뇌졸중의 주요 억제 요인입니다.
대다수의 환자들은 생계에 영향을 미치는 평생 장애를 겪을 뿐만 아니라, 사회경제적으로도 막대한 영향을 미칩니다. 기술 발전으로 진단 비용 또한 증가했습니다.
예를 들어,
의료 연구 및 품질 기관에 따르면 허혈성 뇌졸중의 평균 입원 기간(진단 및 입원 포함)은 입원당 9,100달러로 5.6일이고, 출혈성 뇌졸중의 경우 입원당 19,500달러로 8.4일입니다.
- 제품 리콜 증가
전문가들은 다양한 연령대의 환자를 대상으로 다양한 시술을 시행하기 위해 다양한 뇌졸중 진단 기기를 사용합니다. 따라서 이러한 기기 사용과 관련된 부작용과 합병증은 환자에게 심각한 해를 끼칠 수 있습니다.
이러한 진단 기기 및 제품은 매우 고가이고 위험도가 높아 잠재적인 고장 발생 시 환자에게 심각한 결과를 초래할 수 있습니다. 따라서 환자의 안전을 위해 엄격한 규제 및 리콜이 시행되고 있습니다.
예를 들어,
Neusoft Medical Systems Co., Ltd.의 제품인 NeuViz 64 멀티 슬라이스 CT 스캐너 시스템 제품은 전신 컴퓨터 단층촬영(CT)용 멀티 슬라이스 CT 스캐너 시스템으로, 지속적으로 회전하는 X선관과 검출기 어레이를 특징으로 하며, 시스템에 소프트웨어 오류가 있어 FDA에서 리콜되었습니다.
이 시장 보고서는 최근 동향, 무역 규제, 수출입 분석, 생산 분석, 가치 사슬 최적화, 시장 점유율, 국내 및 현지 시장 참여자의 영향, 신규 매출 창출 기회 분석, 시장 규제 변화, 전략적 시장 성장 분석, 시장 규모, 카테고리별 시장 성장, 응용 분야별 틈새 시장 및 시장 지배력, 제품 승인, 제품 출시, 지리적 확장, 시장 기술 혁신 등에 대한 세부 정보를 제공합니다. 시장에 대한 자세한 정보를 원하시면 Data Bridge Market Research에 문의하여 분석 브리핑을 요청해 주십시오. 저희 팀은 시장 성장을 위한 정보에 기반한 시장 결정을 내릴 수 있도록 도와드리겠습니다.
뇌졸중 시장 범위
시장은 유형, 진단 및 치료, 성별, 최종 사용자, 유통 채널을 기준으로 다섯 가지 주요 세그먼트로 분류됩니다. 이러한 세그먼트의 성장은 산업 내 저조한 성장 세그먼트를 분석하고, 사용자에게 핵심 시장 응용 분야를 파악하기 위한 전략적 의사 결정에 도움이 되는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 될 것입니다.
유형
- 허혈성 뇌졸중
- 혈전성(뇌혈전증)
- 색전증(뇌색전증)
- 출혈성 뇌졸중
- 지주막하출혈
- 뇌내출혈
- 일과성 허혈 발작(TIA)
진단 및 치료
- 치료
- 약물
- 클래스별로
- 혈압약
- 안지오텐신 전환 효소(ACE) 억제제
- 라미프릴
- 리시노프릴
- 에날라프릴
- 페린도프릴
- 다른
- 티아지드 이뇨제
- 인다파마이드
- 벤드로플루메티아지드
- 스피로노락톤
- 아밀로라이드
- 다른
- 칼슘 채널 차단제
- 암로디핀
- 니페디핀
- 베라파밀
- 니카르디핀
- 펠로디핀
- 니모디핀
- 다른
- 베타 차단제
- 아테놀롤
- 비스오프롤롤
- 라베톨롤
- 기타
- 알파 차단제
- 독사조신
- 기타
- 기타
- 안지오텐신 전환 효소(ACE) 억제제
- 항혈소판제
- 아스피린
- 클로피도그렐
- 디피리다몰
- 티클로피딘
- 기타
- 항응고제
- 와파린
- 아픽사반
- 다비가트란
- 헤파린
- 리바록사반
- 다른
- 조직 플라스미노겐 활성제(TPA)
- 알테플라제
- 테넥테플라제
- 레테플라제
- 아니스트레플라제
- 다른
- 스타틴
- 아토르바스타틴
- 심바스타틴
- 로바스타틴
- 로수바스타틴
- 플루바스타틴
- 프라바스타틴
- 피타바스타틴
- 기타
- 비타민 K
- 지지 약물
- 영양 보충제
- 해열제
- 기타
- 혈압약
- 약물 유형별
- 브랜드
- 액티베이즈
- 에도박산
- 쿠마딘
- 헤파린 레오
- 듀오플라빈
- 아그레녹스
- 레타바세
- 얀토벤
- 카스트로
- 다른
- 브랜드
- 일반적인
- 투여 경로별
- 경구
- 태블릿
- 캡슐
- 기타
- 비경구
- 정맥
- 피하
- 기타
- 경구
- 구매 방식별
- 처방
- 처방전 없이 구입 가능한(OTC)
- 치료 유형별
- 복합 치료
- 단독요법
- 투여 경로별
- 수술
- 색전 코일
- 흡인 카테터
- 스텐트 리트리버
- 수술용 클리핑
- 기타
- 기타 치료
- 물리 치료
- 작업 요법
- 언어 치료
- 기타
- 클래스별로
- 진단
- 영상 검사
- 컴퓨터 단층촬영(CT) 스캔
- 자기공명영상(MRI)
- 경동맥 초음파
- 뇌혈관조영술
- 혈액 검사
- 심초음파
- 요추 천자
- 기타
- 영상 검사
- 약물
성별
- 여성
- 남성
최종 사용자
- 병원 및 진료소
- 전문 클리닉
- 외래 수술 센터
- 홈케어
- 실험실
- 기타
유통 채널
- 직접
- 소매
- 온라인
뇌졸중 시장 지역 분석
위에 언급된 대로 유형, 진단 및 치료, 성별, 최종 사용자, 유통 채널별로 시장을 분석하고 시장 규모에 대한 통찰력과 추세를 제공합니다.
이 시장에서 다루는 국가는 미국, 캐나다, 멕시코, 독일, 프랑스, 영국, 네덜란드, 스위스, 러시아, 이탈리아, 스페인, 터키, 오스트리아, 폴란드, 노르웨이, 아일랜드, 유럽 기타 지역, 중국, 일본, 인도, 한국, 싱가포르, 말레이시아, 호주, 태국, 인도네시아, 필리핀, 베트남, 대만, 아시아 태평양 기타 지역, 사우디아라비아, UAE, 남아프리카 공화국, 이집트, 이스라엘, 쿠웨이트, 중동 및 아프리카 기타 지역, 브라질, 아르헨티나, 칠레, 페루, 남미 기타 지역입니다.
북미 지역은 높은 의료비 지출, 선진 의료 인프라, 포괄적인 뇌졸중 치료 프로그램 덕분에 글로벌 뇌졸중 시장을 주도할 것으로 예상됩니다.
아시아 태평양 지역은 뇌졸중 예방에 대한 인식 제고, 의료 서비스 접근성 향상, 노령 인구 증가로 인해 예측 기간 동안 글로벌 뇌졸중 시장에서 가장 빠르게 성장하는 지역입니다.
보고서의 국가별 섹션은 개별 시장 영향 요인과 국내 시장 규제 변화도 제시하며, 이는 현재 및 미래 시장 동향에 영향을 미칩니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 동향, 포터의 5가지 경쟁 요인 분석, 사례 연구 등의 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 활용됩니다. 또한, 글로벌 브랜드의 존재 및 가용성, 그리고 국내 및 국내 브랜드와의 경쟁이 심화되거나 부족해짐에 따라 직면하는 과제, 국내 관세 및 무역 경로의 영향 등을 고려하여 국가별 데이터를 예측 분석합니다.
뇌졸중 시장 점유율
시장 경쟁 구도는 경쟁사별 세부 정보를 제공합니다. 여기에는 회사 개요, 회사 재무 상태, 매출 창출, 시장 잠재력, 연구 개발 투자, 신규 시장 진출, 글로벌 입지, 생산 시설 및 설비, 생산 능력, 회사의 강점과 약점, 제품 출시, 제품 종류 및 범위, 응용 분야별 우위 등이 포함됩니다. 위에 제공된 데이터는 해당 회사의 시장 집중도와 관련된 데이터입니다.
시장에서 운영되는 뇌졸중 시장 선두주자는 다음과 같습니다.
- 브리스톨-마이어스 스퀴브 회사(미국)
- 베링거 인겔하임 인터내셔널 GmbH(독일)
- F. 호프만-라 로슈 유한회사(스위스)
- 다이이치산쿄 주식회사(일본)
- 사노피(프랑스)
- 존슨앤드존슨 서비스 주식회사(미국)
- 바이엘 AG(독일)
- Sandoz AG(스위스)
- 화이자(미국)
- 메드트로닉(아일랜드)
- 애벗(미국)
- Viatris Inc. (미국)
- 아스트라제네카(영국)
- 페넘브라 주식회사(미국)
- GLENMARK PHARMACEUTICALS LTD(인도)
- Fresenius SE & Co. KGaA(독일)
- Teva Pharmaceuticals USA, Inc. (이스라엘)
- 루팡(인도)
- Amneal Pharmaceuticals LLC(미국)
뇌졸중 시장의 최신 동향
- 2023년 7월, 로슈는 고혈압 치료를 위한 2상 임상 시험 중인 RNAi 치료제인 질레베시르(zilebesir)의 개발 및 상용화를 위해 알나일람(Alnylam)과 새로운 파트너십을 발표했습니다. 이번 협력은 알나일람의 입증된 RNAi 치료 경험과 로슈의 글로벌 시장 진출, 혁신에 대한 헌신, 그리고 심각한 심혈관 질환 환자의 삶의 질을 변화시키고자 하는 열망이 결합된 결과입니다.
- 2020년 9월, 다이이치산쿄 주식회사는 비판막성 심방세동(non-valvular regurgitation) 및 중증 출혈을 동반한 고령 환자를 대상으로 항응고제 에독사반(에독사반 벤조에이트 수화물)의 연장 승인을 위한 추가 신청서를 일본에 제출했다고 발표했습니다. 위험. 이 신청서는 출혈 위험이 높고 다른 항응고제 치료에 적합하지 않은 80세 이상의 비판막성 심방세동 환자 984명을 대상으로 한 일본 3상 임상시험(ELDERCARE-AF 시험) 결과를 기반으로 합니다. 다이이치산쿄는 새로운 치료 옵션을 제공함으로써 고령의 비판막성 심방세동 환자 치료에 기여할 계획입니다.
- 2022년 7월, 세계 최고의 제네릭 및 바이오시밀러 제조업체인 산도스는 슬로베니아 류블랴나에 위치한 자사 시설에 약 9천만 달러를 투자하여 2026년까지 산도스 바이오파마 개발 센터를 설립한다고 발표했습니다. 이번 투자로 류블랴나 시설은 산도스의 가장 중요한 바이오시밀러 제품 개발 시설 중 하나가 될 것입니다. 새로운 사무실은 약 200개의 새로운 정규직 일자리를 창출하고, 바이오시밀러 및 의약품 개발 역량을 더욱 강화할 것입니다.
- 2023년 1월, 혁신적인 치료법 개발에 주력하는 글로벌 헬스케어 기업 페넘브라(Penumbra, Inc.)는 시중에서 가장 진보적이고 강력한 기계적 혈전 제거 시스템인 라이트닝 플래시(Lightning Flash™)의 미국 식품의약국(FDA) 승인 및 출시를 발표했습니다. 라이트닝 플래시는 페넘브라의 새로운 라이트닝 인텔리전트 애스펙션(Lightning Intelligent Aspiration) 기술을 탑재했으며, 이 기술은 두 가지 혈전 감지 알고리즘을 갖추고 있습니다. 혁신적인 카테터 기술과 결합된 라이트닝 플래시는 정맥색전증 및 폐색전증(PE)을 포함한 체내의 큰 혈전을 신속하게 제거하도록 설계되었습니다. 이 신기술의 뛰어난 추적성과 흐르는 혈액과 혈전을 구별하는 독보적인 능력 덕분에 이번 출시는 페넘브라의 제품 포트폴리오 확장에 도움이 될 것입니다.
- 2023년 8월, 루핀은 심장 건강 전문 환자 지원 프로그램인 Jeet의 출시를 발표했습니다. 이 프로그램의 출시는 질병 관련 스트레스로부터의 자유와 더 행복하고 건강한 삶으로의 여정을 상징하는 인도의 77번째 독립기념일과 맞물려 진행됩니다. Jeet은 비용 절감, 의료 지원, 복약 알림, 생활 습관 지원 등 다양한 혜택을 제공하여 심혈관 치료 분야의 신뢰할 수 있는 파트너가 되고 있습니다. Jeet은 심혈관 질환 및 동반 질환에 대한 인식을 높여 의사와 환자의 경험을 개선하는 통합적인 접근 방식을 제공합니다. 이 앱에는 더 건강한 생활 습관을 장려하고 건강한 심장을 지원하도록 설계된 기능들이 포함되어 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 LIMITATIONS
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 GLOBAL STROKE MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN U.S.
5.2 REGULATION IN EUROPE
5.3 REGULATION IN CHINA
5.4 REGULATION IN JAPAN
5.5 REGULATION IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSIS
6.2.2 INCREASE IN PRODUCT RECALL
6.3 OPPORTUNITIES
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT
6.4 CHALLENGES
6.4.1 FALSE DIAGNOSIS IN STROKES
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE
7 GLOBAL STROKE MARKET, BY TYPE
7.1 OVERVIEW
7.2 ISCHEMIC STROKE
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS)
7.2.2 EMBOLIC (CEREBRAL EMBOLISM)
7.3 HEMORRHAGIC STROKE
7.3.1 SUBARACHNOID HEMORRHAGE
7.3.2 INTRACEREBRAL HEMORRHAGE
7.4 TRANSIENT ISCHEMIC ATTACT (TIA)
8 GLOBAL STROKE MARKET, BY GENDER
8.1 OVERVIEW
8.2 FEMALE
8.3 MALE
9 GLOBAL STROKE MARKET, BY DIAGNOSIS AND TREATMENT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 BY TREATMENT TYPE
9.2.1.1 MEDICATION
9.2.1.1.1 MEDICATION, BY CLASS
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
9.2.1.1.1.1.2 RAMIPRIL
9.2.1.1.1.1.3 LISINOPRIL
9.2.1.1.1.1.4 ENALAPRIL
9.2.1.1.1.1.5 PERINDOPRIL
9.2.1.1.1.1.6 OTHER
9.2.1.1.1.2 THIAZIDE DIURETICS
9.2.1.1.1.2.1 INDAPAMIDE
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE
9.2.1.1.1.2.3 SPIRONOLACTONE
9.2.1.1.1.2.4 AMILORIDE
9.2.1.1.1.2.5 OTHER
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS
9.2.1.1.1.3.1 AMLODIPINE
9.2.1.1.1.3.2 NIFEDIPINE
9.2.1.1.1.3.3 VERAPAMIL
9.2.1.1.1.3.4 NICARDIPINE
9.2.1.1.1.3.5 FELODIPINE
9.2.1.1.1.3.6 NIMODIPINE
9.2.1.1.1.3.7 OTHERS
9.2.1.1.1.4 BETA BLOCKERS
9.2.1.1.1.4.1 ATENOLOL
9.2.1.1.1.4.2 BISOPROLOL
9.2.1.1.1.4.3 LABETOLOL
9.2.1.1.1.4.4 OTHERS
9.2.1.1.1.5 ALPHA-BLOCKERS
9.2.1.1.1.5.1 DOXAZOSIN
9.2.1.1.1.5.2 OTHERS
9.2.1.1.1.6 OTHERS
9.2.1.1.1.7 ANTIPLATELET DRUGS
9.2.1.1.1.7.1 ASPIRIN
9.2.1.1.1.7.2 CLOPIDOGREL
9.2.1.1.1.7.3 DIPYRIDAMOLE
9.2.1.1.1.7.4 TICLOPIDINE
9.2.1.1.1.7.5 OTHERS
9.2.1.1.1.8 ANTICOAGULANTS
9.2.1.1.1.8.1 WARFARIN
9.2.1.1.1.8.2 APIXABAN
9.2.1.1.1.8.3 DABIGATRAN
9.2.1.1.1.8.4 HEPARIN
9.2.1.1.1.8.5 RIVAROXABAN
9.2.1.1.1.8.6 OTHERS
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA)
9.2.1.1.1.9.1 ALTEPLASE
9.2.1.1.1.9.2 TENECTEPLASE
9.2.1.1.1.9.3 RETEPLASE
9.2.1.1.1.9.4 ANISTREPLASE
9.2.1.1.1.9.5 OTHERS
9.2.1.1.1.10 STATINS
9.2.1.1.1.10.1.1 ATORVASTATIN
9.2.1.1.1.10.1.2 SIMVASTATIN
9.2.1.1.1.10.1.3 LOVASTATIN
9.2.1.1.1.10.1.4 ROSUVASTATIN
9.2.1.1.1.10.1.5 FLUVASTATIN
9.2.1.1.1.10.1.6 PRAVASTATIN
9.2.1.1.1.10.1.7 PITAVASTATIN
9.2.1.1.1.10.1.8 OTHERS
9.2.1.1.1.11 VITAMIN K
9.2.1.1.1.12 SUPPORTIVE MEDICATION
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS
9.2.1.1.1.12.2 ANTIPYRETICS
9.2.1.1.1.12.3 OTHERS
9.2.1.1.2 MEDICATION, BY DRUG TYPE
9.2.1.1.2.1 BRANDED
9.2.1.1.2.1.1 ACTIVASE
9.2.1.1.2.1.2 EDOBAXAN
9.2.1.1.2.1.3 COUMADIN
9.2.1.1.2.1.4 HEPARIN LEO
9.2.1.1.2.1.5 DUOPLAVIN
9.2.1.1.2.1.6 AGGRENOX
9.2.1.1.2.1.7 RETAVASE
9.2.1.1.2.1.8 JANTOVEN
9.2.1.1.2.1.9 CATHFLO
9.2.1.1.2.1.10 OTHER
9.2.1.1.2.2 GENERIC
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION
9.2.1.1.3.1 ORAL
9.2.1.1.3.1.1 TABLET
9.2.1.1.3.1.2 CAPSULES
9.2.1.1.3.1.3 OTHERS
9.2.1.1.3.2 PARENTERAL
9.2.1.1.3.2.1 INTRAVENOUS
9.2.1.1.3.2.2 SUBCUTANEOUS
9.2.1.1.3.3 OTHERS
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE
9.2.1.1.4.1 PRESCRIPTION
9.2.1.1.4.2 OVER THE COUNTER (OTC)
9.2.1.1.5 MEDICATION, BY THERAPY TYPE
9.2.1.1.5.1 COMBINATION THERAPY
9.2.1.1.5.2 MONOTHERAPY
9.2.1.2 SURGERY
9.2.1.2.1 EMBOLIC COILS
9.2.1.2.2 ASPIRATION CATHETERS
9.2.1.2.3 STENT RETRIEVER
9.2.1.2.4 SURGICAL CLIPPING
9.2.1.2.5 OTHERS
9.2.1.3 OTHERS THERAPY
9.2.1.3.1 PHYSICAL THERAPY
9.2.1.3.2 OCCUPATIONAL THERAPY
9.2.1.3.3 SPEECH THERAPY
9.2.1.3.4 OTHERS
9.3 DIAGNOSIS
9.3.1 IMAGING TEST
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI)
9.3.1.3 CAROTID ULTRASOUND
9.3.1.4 CEREBRAL ANGIOGRAM
9.3.2 BLOOD TEST
9.3.3 ECHOCARDIOGRAM
9.3.4 LUMBAR PUNCTURE
9.3.5 OTHERS
10 GLOBAL STROKE MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT
10.3 RETAIL
10.4 ONLINE
11 GLOBAL STROKE MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 SPECIALTY CLINICS
11.4 AMBULATORY SURGICAL CENTER
11.5 HOMECARE
11.6 LABORATORIES
11.7 OTHERS
12 GLOBAL STROKE MARKET, BY REGION
12.1 OVERVIEW
12.2 NORTH AMERICA
12.2.1 U.S
12.2.2 CANADA
12.2.3 MEXICO
12.3 EUROPE
12.3.1 GERMANY
12.3.2 U.K.
12.3.3 FRANCE
12.3.4 ITALY
12.3.5 SPAIN
12.3.6 RUSSIA
12.3.7 NETHERLANDS
12.3.8 SWITZERLAND
12.3.9 TURKEY
12.3.10 AUSTRIA
12.3.11 POLAND
12.3.12 NORWAY
12.3.13 IRELAND
12.3.14 REST OF EUROPE
12.4 ASIA-PACIFIC
12.4.1 CHINA
12.4.2 JAPAN
12.4.3 INDIA
12.4.4 AUSTRALIA
12.4.5 SOUTH KOREA
12.4.6 SINGAPORE
12.4.7 THAILAND
12.4.8 PHILIPPINES
12.4.9 MALAYSIA
12.4.10 INDONESIA
12.4.11 VIETNAM
12.4.12 TAIWAN
12.4.13 REST OF ASIA-PACIFIC
12.5 SOUTH AMERICA
12.5.1 BRAZIL
12.5.2 ARGENTINA
12.5.3 CHILE
12.5.4 PERU
12.5.5 REST OF SOUTH AMERICA
12.6 MIDDLE EAST AND AFRICA
12.6.1 SOUTH AFRICA
12.6.2 SAUDI ARABIA
12.6.3 EGYPT
12.6.4 U.A.E.
12.6.5 ISRAEL
12.6.6 KUWAIT
13 GLOBAL STROKE MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3 COMPANY SHARE ANALYSIS: EUROPE
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 BRISTOL-MYERS SQUIBB COMPANY
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 DAIICHI SANKYO COMPANY, LIMITED
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 SANOFI
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMNEAL PHARMACEUTICALS LLC
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ASTRAZENECA
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 FRESENIUS SE & CO. KGAA
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 GLENMARK PHARMACEUTICALS LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 JOHNSON & JOHNSON SERVICES, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MEDTRONIC
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 PENUMBRA, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 PFIZER INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 SANDOZ AG
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICALS USA, INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
표 목록
TABLE 1 GLOBAL STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 GLOBAL ISCHEMIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 GLOBAL ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 GLOBAL HEMORRHAGIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 GLOBAL HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 GLOBAL TRANSIENT ISCHEMIC ATTACT (TIA) IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 GLOBAL STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 8 GLOBAL FEMALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL MALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL TREATMENT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL BLOOD PRESSURE MEDICINES IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 21 GLOBAL ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 GLOBAL OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 GLOBAL DIAGNOSIS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 GLOBAL DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 GLOBAL IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 GLOBAL STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 GLOBAL DIRECT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 GLOBAL RETAIL IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 GLOBAL ONLINE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 GLOBAL STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 GLOBAL HOSPITALS & CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 GLOBAL SPECIALTY CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 GLOBAL AMBULATORY SURGICAL CENTER IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 GLOBAL HOMECARE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 GLOBAL LABORATORIES IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 GLOBAL OTHERS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 GLOBAL STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH-AMERICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH-AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH-AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH-AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH-AMERICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH-AMERICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH-AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH-AMERICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH-AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH-AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH-AMERICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH-AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH-AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH-AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH-AMERICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH-AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH-AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH-AMERICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH-AMERICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH-AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH-AMERICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 NORTH-AMERICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 NORTH-AMERICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 NORTH-AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 NORTH-AMERICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 79 NORTH-AMERICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 80 NORTH-AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 81 U.S. STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 U.S. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 U.S. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 U.S. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 85 U.S. TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 U.S. MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 87 U.S. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 88 U.S. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 89 U.S. THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 90 U.S. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 97 U.S. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 U.S. PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 U.S. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 104 U.S. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 U.S. SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 U.S. OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 U.S. DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 U.S. IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 U.S. STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 110 U.S. STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 111 U.S. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 112 CANADA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 CANADA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 CANADA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 CANADA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 116 CANADA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 CANADA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 118 CANADA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 119 CANADA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 124 CANADA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 125 CANADA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 126 CANADA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 127 CANADA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 128 CANADA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 129 CANADA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 CANADA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 CANADA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 132 CANADA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 CANADA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 CANADA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 135 CANADA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 CANADA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 CANADA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 CANADA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 CANADA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 CANADA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 141 CANADA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 142 CANADA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 143 MEXICO STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 MEXICO ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 MEXICO HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 MEXICO STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 147 MEXICO TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 MEXICO MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 149 MEXICO BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 150 MEXICO ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 151 MEXICO THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 152 MEXICO CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 153 MEXICO BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 154 MEXICO ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 155 MEXICO ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 156 MEXICO ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 157 MEXICO TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 158 MEXICO STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 159 MEXICO SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 160 MEXICO MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 MEXICO BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 MEXICO MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 163 MEXICO ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 MEXICO PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 MEXICO MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 166 MEXICO MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 MEXICO SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 MEXICO OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 MEXICO DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 MEXICO IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 MEXICO STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 172 MEXICO STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 173 MEXICO STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 EUROPE STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 175 EUROPE STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 EUROPE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 EUROPE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 EUROPE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 179 EUROPE TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 EUROPE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 181 EUROPE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 182 EUROPE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 183 EUROPE THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 184 EUROPE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 185 EUROPE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 186 EUROPE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 187 EUROPE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 188 EUROPE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 189 EUROPE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 190 EUROPE STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 191 EUROPE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 192 EUROPE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 EUROPE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 EUROPE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 195 EUROPE ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 EUROPE PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 EUROPE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 198 EUROPE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 EUROPE SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 EUROPE OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 EUROPE DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 EUROPE IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 EUROPE STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 204 EUROPE STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 205 EUROPE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 206 GERMANY STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 GERMANY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 GERMANY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 GERMANY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 210 GERMANY TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 GERMANY MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 212 GERMANY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 213 GERMANY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 214 GERMANY THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 215 GERMANY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 216 GERMANY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 217 GERMANY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 218 GERMANY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 219 GERMANY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 220 GERMANY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 221 GERMANY STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 222 GERMANY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 223 GERMANY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 GERMANY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 GERMANY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 226 GERMANY ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 GERMANY PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 GERMANY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 229 GERMANY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 GERMANY SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 GERMANY OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 GERMANY DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 GERMANY IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 GERMANY STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 235 GERMANY STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 236 GERMANY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 237 U.K. STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 U.K. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 U.K. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 U.K. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 241 U.K. TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 U.K. MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 243 U.K. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 U.K. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 245 U.K. THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 246 U.K. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 247 U.K. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 248 U.K. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 249 U.K. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 250 U.K. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 251 U.K. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 252 U.K. STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 253 U.K. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 254 U.K. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 U.K. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 U.K. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 257 U.K. ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 U.K. PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 U.K. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 260 U.K. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 U.K. SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 U.K. OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 U.K. DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 U.K. IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 U.K. STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 266 U.K. STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 267 U.K. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 268 FRANCE STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 FRANCE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 FRANCE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 FRANCE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 272 FRANCE TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 FRANCE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 274 FRANCE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 275 FRANCE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 276 FRANCE THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 277 FRANCE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 278 FRANCE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 279 FRANCE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 280 FRANCE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 281 FRANCE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 282 FRANCE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 283 FRANCE STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 284 FRANCE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 285 FRANCE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 FRANCE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 FRANCE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 288 FRANCE ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 FRANCE PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 FRANCE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 291 FRANCE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 292 FRANCE SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 FRANCE OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 FRANCE DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 FRANCE IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 FRANCE STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 297 FRANCE STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 298 FRANCE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 299 ITALY STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 ITALY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 ITALY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 ITALY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 303 ITALY TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 ITALY MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 305 ITALY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 306 ITALY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 307 ITALY THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 308 ITALY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 309 ITALY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 310 ITALY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 311 ITALY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 312 ITALY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 313 ITALY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 314 ITALY STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 315 ITALY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 316 ITALY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 ITALY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 ITALY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 319 ITALY ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 ITALY PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 ITALY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 322 ITALY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 ITALY SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 ITALY OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 ITALY DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 ITALY IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 ITALY STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 328 ITALY STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 329 ITALY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 330 SPAIN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 SPAIN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 SPAIN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 SPAIN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 334 SPAIN TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 SPAIN MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 336 SPAIN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 337 SPAIN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 338 SPAIN THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 339 SPAIN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 340 SPAIN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 341 SPAIN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 342 SPAIN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 343 SPAIN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 344 SPAIN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 345 SPAIN STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 346 SPAIN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 347 SPAIN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 SPAIN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 SPAIN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 350 SPAIN ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 SPAIN PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 SPAIN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 353 SPAIN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 SPAIN SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 SPAIN OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 SPAIN DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 SPAIN IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 SPAIN STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 359 SPAIN STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 360 SPAIN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 361 RUSSIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 RUSSIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 363 RUSSIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 RUSSIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 365 RUSSIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 RUSSIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 367 RUSSIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 368 RUSSIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 369 RUSSIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 370 RUSSIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 371 RUSSIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 372 RUSSIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 373 RUSSIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 374 RUSSIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 375 RUSSIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 376 RUSSIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 377 RUSSIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 378 RUSSIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 RUSSIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 380 RUSSIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 381 RUSSIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 RUSSIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 RUSSIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 384 RUSSIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 RUSSIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 RUSSIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 RUSSIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 RUSSIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 RUSSIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 390 RUSSIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 391 RUSSIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 392 NETHERLANDS STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 NETHERLANDS ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 NETHERLANDS HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 NETHERLANDS STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 396 NETHERLANDS TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 NETHERLANDS MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 398 NETHERLANDS BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 399 NETHERLANDS ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 400 NETHERLANDS THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 401 NETHERLANDS CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 402 NETHERLANDS BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 403 NETHERLANDS ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 404 NETHERLANDS ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 405 NETHERLANDS ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 406 NETHERLANDS TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 407 NETHERLANDS STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 408 NETHERLANDS SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 409 NETHERLANDS MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 NETHERLANDS BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 NETHERLANDS MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 412 NETHERLANDS ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 NETHERLANDS PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 NETHERLANDS MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 415 NETHERLANDS MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 NETHERLANDS SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 NETHERLANDS OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 NETHERLANDS DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 NETHERLANDS IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 NETHERLANDS STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 421 NETHERLANDS STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 422 NETHERLANDS STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 423 SWITZERLAND STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 SWITZERLAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 SWITZERLAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 SWITZERLAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 427 SWITZERLAND TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 428 SWITZERLAND MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 429 SWITZERLAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 430 SWITZERLAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 431 SWITZERLAND THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 432 SWITZERLAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 433 SWITZERLAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 434 SWITZERLAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 435 SWITZERLAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 436 SWITZERLAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 437 SWITZERLAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 438 SWITZERLAND STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 439 SWITZERLAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 440 SWITZERLAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 SWITZERLAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 SWITZERLAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 443 SWITZERLAND ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 444 SWITZERLAND PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 445 SWITZERLAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 446 SWITZERLAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 447 SWITZERLAND SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 448 SWITZERLAND OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 SWITZERLAND DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 SWITZERLAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 SWITZERLAND STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 452 SWITZERLAND STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 453 SWITZERLAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 454 TURKEY STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 TURKEY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 TURKEY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 TURKEY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 458 TURKEY TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 TURKEY MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 460 TURKEY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 461 TURKEY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 462 TURKEY THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 463 TURKEY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 464 TURKEY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 465 TURKEY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 466 TURKEY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 467 TURKEY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 468 TURKEY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 469 TURKEY STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 470 TURKEY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 471 TURKEY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 TURKEY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 TURKEY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 474 TURKEY ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 TURKEY PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 TURKEY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 477 TURKEY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 TURKEY SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 TURKEY OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 TURKEY DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 TURKEY IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 TURKEY STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 483 TURKEY STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 484 TURKEY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 485 AUSTRIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 AUSTRIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 AUSTRIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 AUSTRIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 489 AUSTRIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 AUSTRIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 491 AUSTRIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 492 AUSTRIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 493 AUSTRIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 494 AUSTRIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 495 AUSTRIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 496 AUSTRIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 497 AUSTRIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 498 AUSTRIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 499 AUSTRIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 500 AUSTRIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 501 AUSTRIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 502 AUSTRIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 AUSTRIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 AUSTRIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 505 AUSTRIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 AUSTRIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 AUSTRIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 508 AUSTRIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 AUSTRIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 AUSTRIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 AUSTRIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 AUSTRIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 513 AUSTRIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 514 AUSTRIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 515 AUSTRIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 516 POLAND STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 POLAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 518 POLAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 POLAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 520 POLAND TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 POLAND MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 522 POLAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 523 POLAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 524 POLAND THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 525 POLAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 526 POLAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 527 POLAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 528 POLAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 529 POLAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 530 POLAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 531 POLAND STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 532 POLAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 533 POLAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 POLAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 POLAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 536 POLAND ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 POLAND PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 538 POLAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 539 POLAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 POLAND SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 541 POLAND OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 542 POLAND DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 POLAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 544 POLAND STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 545 POLAND STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 546 POLAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 547 NORWAY STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 548 NORWAY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 NORWAY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 NORWAY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 551 NORWAY TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 NORWAY MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 553 NORWAY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 554 NORWAY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 555 NORWAY THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 556 NORWAY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 557 NORWAY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 558 NORWAY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 559 NORWAY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 560 NORWAY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 561 NORWAY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 562 NORWAY STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 563 NORWAY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 564 NORWAY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 NORWAY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 NORWAY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 567 NORWAY ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 NORWAY PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 NORWAY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 570 NORWAY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 NORWAY SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 NORWAY OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 NORWAY DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 NORWAY IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 575 NORWAY STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 576 NORWAY STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 577 NORWAY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 578 IRELAND STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 IRELAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 580 IRELAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 581 IRELAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 582 IRELAND TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 583 IRELAND MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 584 IRELAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 585 IRELAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 586 IRELAND THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 587 IRELAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 588 IRELAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 589 IRELAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 590 IRELAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 591 IRELAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 592 IRELAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 593 IRELAND STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 594 IRELAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 595 IRELAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 IRELAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 IRELAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 598 IRELAND ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 599 IRELAND PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 IRELAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 601 IRELAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 IRELAND SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 603 IRELAND OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 IRELAND DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 605 IRELAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 IRELAND STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 607 IRELAND STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 608 IRELAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 609 REST OF EUROPE STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 ASIA-PACIFIC STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 611 ASIA-PACIFIC STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 ASIA-PACIFIC ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 ASIA-PACIFIC HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 614 ASIA-PACIFIC STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 615 ASIA-PACIFIC TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 617 ASIA-PACIFIC BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 618 ASIA-PACIFIC ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 619 ASIA-PACIFIC THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 620 ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 621 ASIA-PACIFIC BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 622 ASIA-PACIFIC ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 623 ASIA-PACIFIC ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 624 ASIA-PACIFIC ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 625 ASIA-PACIFIC TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 626 ASIA-PACIFIC STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 627 ASIA-PACIFIC SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 628 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 ASIA-PACIFIC BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 631 ASIA-PACIFIC ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 632 ASIA-PACIFIC PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 633 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 634 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 ASIA-PACIFIC SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 ASIA-PACIFIC OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 ASIA-PACIFIC DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 ASIA-PACIFIC IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 ASIA-PACIFIC STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 640 ASIA-PACIFIC STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 641 ASIA-PACIFIC STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 642 CHINA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 643 CHINA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 CHINA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 CHINA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 646 CHINA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 647 CHINA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 648 CHINA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 649 CHINA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 650 CHINA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 651 CHINA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 652 CHINA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 653 CHINA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 654 CHINA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 655 CHINA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 656 CHINA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 657 CHINA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 658 CHINA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 659 CHINA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 CHINA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 CHINA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 662 CHINA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 663 CHINA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 CHINA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 665 CHINA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 CHINA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 CHINA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 668 CHINA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 669 CHINA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 670 CHINA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 671 CHINA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 672 CHINA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 673 JAPAN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 674 JAPAN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 JAPAN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 676 JAPAN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 677 JAPAN TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 678 JAPAN MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 679 JAPAN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 680 JAPAN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 681 JAPAN THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 682 JAPAN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 683 JAPAN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 684 JAPAN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 685 JAPAN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 686 JAPAN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 687 JAPAN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 688 JAPAN STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 689 JAPAN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 690 JAPAN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 691 JAPAN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 692 JAPAN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 693 JAPAN ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 694 JAPAN PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 695 JAPAN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 696 JAPAN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 697 JAPAN SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 698 JAPAN OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 699 JAPAN DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 700 JAPAN IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 JAPAN STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 702 JAPAN STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 703 JAPAN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 704 INDIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 INDIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 INDIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 INDIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 708 INDIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 INDIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 710 INDIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 711 INDIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 712 INDIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 713 INDIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 714 INDIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 715 INDIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 716 INDIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 717 INDIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 718 INDIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 719 INDIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 720 INDIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 721 INDIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 INDIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 INDIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 724 INDIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 INDIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 INDIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 727 INDIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 728 INDIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 INDIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 730 INDIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 731 INDIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 INDIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 733 INDIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 734 INDIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 735 AUSTRALIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 736 AUSTRALIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 737 AUSTRALIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 738 AUSTRALIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 739 AUSTRALIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 AUSTRALIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 741 AUSTRALIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 742 AUSTRALIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 743 AUSTRALIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 744 AUSTRALIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 745 AUSTRALIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 746 AUSTRALIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 747 AUSTRALIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 748 AUSTRALIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 749 AUSTRALIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 750 AUSTRALIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 751 AUSTRALIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 752 AUSTRALIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 753 AUSTRALIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 AUSTRALIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 755 AUSTRALIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 756 AUSTRALIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 757 AUSTRALIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 758 AUSTRALIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 759 AUSTRALIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 760 AUSTRALIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 761 AUSTRALIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 AUSTRALIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 763 AUSTRALIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 764 AUSTRALIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 765 AUSTRALIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 766 SOUTH KOREA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 SOUTH KOREA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 768 SOUTH KOREA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 SOUTH KOREA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 770 SOUTH KOREA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 771 SOUTH KOREA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 772 SOUTH KOREA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 773 SOUTH KOREA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 774 SOUTH KOREA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 775 SOUTH KOREA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 776 SOUTH KOREA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 777 SOUTH KOREA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 778 SOUTH KOREA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 779 SOUTH KOREA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 780 SOUTH KOREA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 781 SOUTH KOREA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 782 SOUTH KOREA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 783 SOUTH KOREA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 784 SOUTH KOREA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 785 SOUTH KOREA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 786 SOUTH KOREA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 787 SOUTH KOREA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 788 SOUTH KOREA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 789 SOUTH KOREA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 790 SOUTH KOREA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 791 SOUTH KOREA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 792 SOUTH KOREA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 793 SOUTH KOREA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 794 SOUTH KOREA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 795 SOUTH KOREA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 796 SOUTH KOREA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 797 SINGAPORE STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 798 SINGAPORE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 799 SINGAPORE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 800 SINGAPORE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 801 SINGAPORE TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 802 SINGAPORE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 803 SINGAPORE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 804 SINGAPORE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 805 SINGAPORE THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 806 SINGAPORE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 807 SINGAPORE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 808 SINGAPORE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 809 SINGAPORE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 810 SINGAPORE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 811 SINGAPORE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 812 SINGAPORE STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 813 SINGAPORE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 814 SINGAPORE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 815 SINGAPORE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 816 SINGAPORE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 817 SINGAPORE ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 818 SINGAPORE PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 819 SINGAPORE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 820 SINGAPORE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 821 SINGAPORE SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 822 SINGAPORE OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 823 SINGAPORE DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 824 SINGAPORE IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 825 SINGAPORE STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 826 SINGAPORE STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 827 SINGAPORE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 828 THAILAND STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 829 THAILAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 830 THAILAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 831 THAILAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 832 THAILAND TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 833 THAILAND MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 834 THAILAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 835 THAILAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 836 THAILAND THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 837 THAILAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 838 THAILAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 839 THAILAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 840 THAILAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 841 THAILAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 842 THAILAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 843 THAILAND STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 844 THAILAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 845 THAILAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 846 THAILAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 847 THAILAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 848 THAILAND ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 849 THAILAND PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 850 THAILAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 851 THAILAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 852 THAILAND SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 853 THAILAND OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 854 THAILAND DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 855 THAILAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 856 THAILAND STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 857 THAILAND STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 858 THAILAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 859 PHILIPPINES STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 860 PHILIPPINES ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 861 PHILIPPINES HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 862 PHILIPPINES STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 863 PHILIPPINES TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 864 PHILIPPINES MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 865 PHILIPPINES BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 866 PHILIPPINES ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 867 PHILIPPINES THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 868 PHILIPPINES CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 869 PHILIPPINES BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 870 PHILIPPINES ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 871 PHILIPPINES ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 872 PHILIPPINES ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 873 PHILIPPINES TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 874 PHILIPPINES STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 875 PHILIPPINES SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 876 PHILIPPINES MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 877 PHILIPPINES BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 878 PHILIPPINES MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 879 PHILIPPINES ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 880 PHILIPPINES PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 881 PHILIPPINES MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 882 PHILIPPINES MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 883 PHILIPPINES SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 884 PHILIPPINES OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 885 PHILIPPINES DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 886 PHILIPPINES IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 887 PHILIPPINES STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 888 PHILIPPINES STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 889 PHILIPPINES STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 890 MALAYSIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 891 MALAYSIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 892 MALAYSIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 893 MALAYSIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 894 MALAYSIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 895 MALAYSIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 896 MALAYSIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 897 MALAYSIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 898 MALAYSIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 899 MALAYSIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 900 MALAYSIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 901 MALAYSIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 902 MALAYSIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 903 MALAYSIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 904 MALAYSIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 905 MALAYSIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 906 MALAYSIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 907 MALAYSIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 908 MALAYSIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 909 MALAYSIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 910 MALAYSIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 911 MALAYSIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 912 MALAYSIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 913 MALAYSIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 914 MALAYSIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 915 MALAYSIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 916 MALAYSIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 917 MALAYSIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 918 MALAYSIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 919 MALAYSIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 920 MALAYSIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 921 INDONESIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 922 INDONESIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 923 INDONESIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 924 INDONESIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 925 INDONESIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 926 INDONESIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 927 INDONESIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 928 INDONESIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 929 INDONESIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 930 INDONESIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 931 INDONESIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 932 INDONESIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 933 INDONESIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 934 INDONESIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 935 INDONESIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 936 INDONESIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 937 INDONESIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 938 INDONESIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 939 INDONESIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 940 INDONESIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 941 INDONESIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 942 INDONESIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 943 INDONESIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 944 INDONESIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 945 INDONESIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 946 INDONESIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 947 INDONESIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 948 INDONESIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 949 INDONESIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 950 INDONESIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 951 INDONESIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 952 VIETNAM STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 953 VIETNAM ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 954 VIETNAM HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 955 VIETNAM STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 956 VIETNAM TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 957 VIETNAM MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 958 VIETNAM BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 959 VIETNAM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 960 VIETNAM THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 961 VIETNAM CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 962 VIETNAM BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 963 VIETNAM ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 964 VIETNAM ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 965 VIETNAM ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 966 VIETNAM TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 967 VIETNAM STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 968 VIETNAM SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 969 VIETNAM MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 970 VIETNAM BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 971 VIETNAM MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 972 VIETNAM ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 973 VIETNAM PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 974 VIETNAM MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 975 VIETNAM MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 976 VIETNAM SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 977 VIETNAM OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 978 VIETNAM DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 979 VIETNAM IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 980 VIETNAM STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 981 VIETNAM STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 982 VIETNAM STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 983 TAIWAN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 984 TAIWAN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 985 TAIWAN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 986 TAIWAN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 987 TAIWAN TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 988 TAIWAN MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 989 TAIWAN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 990 TAIWAN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 991 TAIWAN THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 992 TAIWAN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 993 TAIWAN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 994 TAIWAN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 995 TAIWAN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 996 TAIWAN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 997 TAIWAN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 998 TAIWAN STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 999 TAIWAN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1000 TAIWAN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1001 TAIWAN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1002 TAIWAN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1003 TAIWAN ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1004 TAIWAN PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1005 TAIWAN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1006 TAIWAN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1007 TAIWAN SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1008 TAIWAN OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1009 TAIWAN DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1010 TAIWAN IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1011 TAIWAN STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1012 TAIWAN STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1013 TAIWAN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1014 REST OF ASIA-PACIFIC STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1015 SOUTH AMERICA STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 1016 SOUTH AMERICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1017 SOUTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1018 SOUTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1019 SOUTH AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1020 SOUTH AMERICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1021 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1022 SOUTH AMERICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1023 SOUTH AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1024 SOUTH AMERICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1025 SOUTH AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1026 SOUTH AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1027 SOUTH AMERICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1028 SOUTH AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1029 SOUTH AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1030 SOUTH AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1031 SOUTH AMERICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1032 SOUTH AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1033 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1034 SOUTH AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1035 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1036 SOUTH AMERICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1037 SOUTH AMERICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1038 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1039 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1040 SOUTH AMERICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1041 SOUTH AMERICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1042 SOUTH AMERICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1043 SOUTH AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1044 SOUTH AMERICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1045 SOUTH AMERICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1046 SOUTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1047 BRAZIL STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1048 BRAZIL ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1049 BRAZIL HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1050 BRAZIL STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1051 BRAZIL TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1052 BRAZIL MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1053 BRAZIL BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1054 BRAZIL ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1055 BRAZIL THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1056 BRAZIL CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1057 BRAZIL BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1058 BRAZIL ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1059 BRAZIL ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1060 BRAZIL ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1061 BRAZIL TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1062 BRAZIL STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1063 BRAZIL SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1064 BRAZIL MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1065 BRAZIL BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1066 BRAZIL MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1067 BRAZIL ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1068 BRAZIL PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1069 BRAZIL MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1070 BRAZIL MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1071 BRAZIL SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1072 BRAZIL OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1073 BRAZIL DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1074 BRAZIL IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1075 BRAZIL STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1076 BRAZIL STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1077 BRAZIL STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1078 ARGENTINA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1079 ARGENTINA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1080 ARGENTINA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1081 ARGENTINA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1082 ARGENTINA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1083 ARGENTINA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1084 ARGENTINA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1085 ARGENTINA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1086 ARGENTINA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1087 ARGENTINA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1088 ARGENTINA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1089 ARGENTINA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1090 ARGENTINA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1091 ARGENTINA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1092 ARGENTINA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1093 ARGENTINA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1094 ARGENTINA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1095 ARGENTINA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1096 ARGENTINA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1097 ARGENTINA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1098 ARGENTINA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1099 ARGENTINA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1100 ARGENTINA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1101 ARGENTINA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1102 ARGENTINA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1103 ARGENTINA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1104 ARGENTINA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1105 ARGENTINA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1106 ARGENTINA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1107 ARGENTINA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1108 ARGENTINA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1109 CHILE STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1110 CHILE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1111 CHILE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1112 CHILE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1113 CHILE TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1114 CHILE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1115 CHILE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1116 CHILE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1117 CHILE THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1118 CHILE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1119 CHILE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1120 CHILE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1121 CHILE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1122 CHILE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1123 CHILE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1124 CHILE STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1125 CHILE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1126 CHILE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1127 CHILE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1128 CHILE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1129 CHILE ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1130 CHILE PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1131 CHILE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1132 CHILE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1133 CHILE SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1134 CHILE OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1135 CHILE DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1136 CHILE IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1137 CHILE STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1138 CHILE STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1139 CHILE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1140 PERU STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1141 PERU ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1142 PERU HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1143 PERU STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1144 PERU TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1145 PERU MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1146 PERU BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1147 PERU ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1148 PERU THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1149 PERU CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1150 PERU BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1151 PERU ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1152 PERU ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1153 PERU ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1154 PERU TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1155 PERU STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1156 PERU SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1157 PERU MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1158 PERU BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1159 PERU MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1160 PERU ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1161 PERU PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1162 PERU MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1163 PERU MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1164 PERU SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1165 PERU OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1166 PERU DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1167 PERU IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1168 PERU STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1169 PERU STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1170 PERU STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1171 REST OF SOUTH AMERICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1172 MIDDLE EAST AND AFRICA STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 1173 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1174 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1175 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1176 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1177 MIDDLE EAST AND AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1178 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1179 MIDDLE EAST AND AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1180 MIDDLE EAST AND AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1181 MIDDLE EAST AND AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1182 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1183 MIDDLE EAST AND AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1184 MIDDLE EAST AND AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1185 MIDDLE EAST AND AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1186 MIDDLE EAST AND AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1187 MIDDLE EAST AND AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1188 MIDDLE EAST AND AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1189 MIDDLE EAST AND AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1190 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1191 MIDDLE EAST AND AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1192 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1193 MIDDLE EAST AND AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1194 MIDDLE EAST AND AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1195 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1196 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1197 MIDDLE EAST AND AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1198 MIDDLE EAST AND AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1199 MIDDLE EAST AND AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1200 MIDDLE EAST AND AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1201 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1202 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1203 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1204 SOUTH AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1205 SOUTH AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1206 SOUTH AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1207 SOUTH AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1208 SOUTH AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1209 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1210 SOUTH AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1211 SOUTH AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1212 SOUTH AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1213 SOUTH AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1214 SOUTH AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1215 SOUTH AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1216 SOUTH AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1217 SOUTH AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1218 SOUTH AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1219 SOUTH AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1220 SOUTH AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1221 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1222 SOUTH AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1223 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1224 SOUTH AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1225 SOUTH AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1226 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1227 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1228 SOUTH AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1229 SOUTH AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1230 SOUTH AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1231 SOUTH AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1232 SOUTH AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1233 SOUTH AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1234 SOUTH AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1235 SAUDI ARABIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1236 SAUDI ARABIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1237 SAUDI ARABIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1238 SAUDI ARABIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1239 SAUDI ARABIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1240 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1241 SAUDI ARABIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1242 SAUDI ARABIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1243 SAUDI ARABIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1244 SAUDI ARABIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1245 SAUDI ARABIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1246 SAUDI ARABIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1247 SAUDI ARABIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1248 SAUDI ARABIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1249 SAUDI ARABIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1250 SAUDI ARABIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1251 SAUDI ARABIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1252 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1253 SAUDI ARABIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1254 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1255 SAUDI ARABIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1256 SAUDI ARABIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1257 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1258 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1259 SAUDI ARABIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1260 SAUDI ARABIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1261 SAUDI ARABIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1262 SAUDI ARABIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1263 SAUDI ARABIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1264 SAUDI ARABIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1265 SAUDI ARABIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1266 EGYPT STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1267 EGYPT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1268 EGYPT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1269 EGYPT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1270 EGYPT TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1271 EGYPT MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1272 EGYPT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1273 EGYPT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1274 EGYPT THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1275 EGYPT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1276 EGYPT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1277 EGYPT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1278 EGYPT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1279 EGYPT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1280 EGYPT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1281 EGYPT STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1282 EGYPT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1283 EGYPT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1284 EGYPT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1285 EGYPT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1286 EGYPT ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1287 EGYPT PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1288 EGYPT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1289 EGYPT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1290 EGYPT SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1291 EGYPT OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1292 EGYPT DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1293 EGYPT IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1294 EGYPT STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1295 EGYPT STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1296 EGYPT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1297 U.A.E. STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1298 U.A.E. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1299 U.A.E. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1300 U.A.E. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1301 U.A.E. TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1302 U.A.E. MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1303 U.A.E. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1304 U.A.E. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1305 U.A.E. THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1306 U.A.E. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1307 U.A.E. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1308 U.A.E. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1309 U.A.E. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1310 U.A.E. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1311 U.A.E. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1312 U.A.E. STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1313 U.A.E. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1314 U.A.E. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1315 U.A.E. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1316 U.A.E. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1317 U.A.E. ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1318 U.A.E. PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1319 U.A.E. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1320 U.A.E. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1321 U.A.E. SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1322 U.A.E. OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1323 U.A.E. DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1324 U.A.E. IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1325 U.A.E. STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1326 U.A.E. STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1327 U.A.E. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1328 ISRAEL STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1329 ISRAEL ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1330 ISRAEL HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1331 ISRAEL STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1332 ISRAEL TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1333 ISRAEL MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1334 ISRAEL BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1335 ISRAEL ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1336 ISRAEL THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1337 ISRAEL CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1338 ISRAEL BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1339 ISRAEL ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1340 ISRAEL ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1341 ISRAEL ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1342 ISRAEL TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1343 ISRAEL STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1344 ISRAEL SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1345 ISRAEL MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1346 ISRAEL BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1347 ISRAEL MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1348 ISRAEL ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1349 ISRAEL PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1350 ISRAEL MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1351 ISRAEL MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1352 ISRAEL SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1353 ISRAEL OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1354 ISRAEL DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1355 ISRAEL IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1356 ISRAEL STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1357 ISRAEL STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1358 ISRAEL STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1359 KUWAIT STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1360 KUWAIT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1361 KUWAIT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1362 KUWAIT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 1363 KUWAIT TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1364 KUWAIT MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1365 KUWAIT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1366 KUWAIT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1367 KUWAIT THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1368 KUWAIT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1369 KUWAIT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1370 KUWAIT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1371 KUWAIT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1372 KUWAIT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1373 KUWAIT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1374 KUWAIT STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1375 KUWAIT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 1376 KUWAIT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1377 KUWAIT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1378 KUWAIT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1379 KUWAIT ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1380 KUWAIT PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1381 KUWAIT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 1382 KUWAIT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1383 KUWAIT SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1384 KUWAIT OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1385 KUWAIT DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 1386 KUWAIT IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1387 KUWAIT STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 1388 KUWAIT STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1389 KUWAIT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1390 REST OF MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 GLOBAL STROKE MARKET: SEGMENTATION
FIGURE 2 GLOBAL STROKE MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL STROKE MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL STROKE MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL STROKE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL STROKE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL STROKE MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL STROKE MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL STROKE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL STROKE MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS IS EXPECTED TO DRIVE THE GLOBAL STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL STROKE MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL STROKE MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL STROKE MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 GLOBAL STROKE MARKET EXECUTIVE SUMMARY
FIGURE 16 STRATEGIC DECISIONS
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL STROKE MARKET
FIGURE 18 GLOBAL STROKE MARKET: BY TYPE, 2024
FIGURE 19 GLOBAL STROKE MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 20 GLOBAL STROKE MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 21 GLOBAL STROKE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 GLOBAL STROKE MARKET: BY GENDER, 2024
FIGURE 23 GLOBAL STROKE MARKET: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 24 GLOBAL STROKE MARKET: BY GENDER, CAGR (2025- 2032)
FIGURE 25 GLOBAL STROKE MARKET: BY GENDER, LIFELINE CURVE
FIGURE 26 GLOBAL STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2024
FIGURE 27 GLOBAL STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 28 GLOBAL STROKE MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)
FIGURE 29 GLOBAL STROKE MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 30 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 31 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
FIGURE 32 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 33 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 GLOBAL STROKE MARKET: BY END USER, 2024
FIGURE 35 GLOBAL STROKE MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 36 GLOBAL STROKE MARKET: BY END USER, CAGR (2025-2032)
FIGURE 37 GLOBAL STROKE MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 GLOBAL STROKE MARKET: SNAPSHOT (2024)
FIGURE 39 GLOBAL STROKE MARKET: COMPANY SHARE 2024 (%)
FIGURE 40 NORTH AMERICA STROKE MARKET: COMPANY SHARE 2024 (%)
FIGURE 41 EUROPE STROKE MARKET: COMPANY SHARE 2024 (%)
FIGURE 42 ASIA-PACIFIC STROKE MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
